Botox Cosmetic expands beyond face for the first time as FDA approves the anti-wrinkle therapy for treating platysma bands.

AbbVie CEO Robert Michael told analysts during the company's second-quarter earnings call in July that “our ex-Humira growth ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...

After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.

Fintel reports that on October 17, 2024, Bernstein initiated coverage of AbbVie (NYSE:ABBV) with a Market Perform ...

The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, ...

There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...

AbbVie announced that the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the ...

IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.0% during the ...